Market by Procedure (Laparoscopy, Orthopedic Surgery, Cardiovascular, Obstetrics and Gynecology, Wound Closure, Plastic & Reconstructive Surgery, Thoracic Surgery, Microvascular, Urology, Neurosurgery, Other Procedures) Type of Infection (Superficial Incisional SSI, Deep Incisional SSI, Organ or Space SSI) Industry Vertical (Hospitals, Ambulatory Surgical Centers) Product (Disinfectants, Manual Reprocessors Solutions, Surgical Drapes, Surgical Gloves, Skin Preparation Solutions, Surgical Irrigation, Surgical Scrubs, Hair Clippers, Medical Nonwovens, Other Products) and Country Outlook | Forecast 2024-2032
According to Triton’s research report, the Asia-Pacific surgical site infection control market is expected to advance at a CAGR of 6.14% over the forecast years 2024-2032.
Report scope can be customized per your requirements - Request Free Sample Report
The surgical site infection control market in the Asia-Pacific region is witnessing significant growth, driven by increasing healthcare expenditures and rising awareness of infection control practices. The World Health Organization (WHO) has emphasized the critical need for improved infection prevention and control (IPC), noting that surgical site infections are among the most common healthcare-associated infections, with an estimated 11% of surgical patients affected in low- and middle-income countries. This has prompted healthcare facilities to adopt stricter infection control protocols, further spurred by government initiatives aimed at reducing healthcare-associated infections.
Moreover, the COVID-19 pandemic heightened the focus on stringent hygiene practices, bolstering the demand for advanced sterilization and disinfection products. The WHO’s ‘Global Guidelines for the Prevention of Surgical Site Infection’ serve as a cornerstone for these improvements, highlighting the importance of evidence-based practices in reducing SSI rates. This heightened focus on infection prevention, along with the expansion of healthcare infrastructure, is expected to drive substantial growth in the studied market across the APAC region.
The countries evaluated in this region include:
China spearheads the regional market, attaining around $325.1 million in 2023
In China, surgical site infections are notably prevalent, with several studies conducted to determine their incidence. One comprehensive study reported an overall SSI rate of around 4.7% across various departments, including internal medicine, oncology, neurology, and obstetrics.
The government has been proactive in addressing the issue of surgical site infections through stringent regulatory frameworks and national guidelines. For instance, the National Health Commission of China has implemented several infection prevention and control (IPC) programs aimed at reducing the incidence of SSIs. These programs are part of broader initiatives to enhance patient safety and improve the quality of healthcare services.
These developments align with the Health China 2030 initiative, which emphasizes the need for improved health outcomes through better healthcare services and infection control.
Market Forecast for India
In India, public hospitals face inadequate administrative and financial support, hindering comprehensive infection control programs. This leads to extremely low nurse-to-patient ratios, particularly in intensive care units, where high HAI rates and overcrowding are common. Several factors, including an aging population, contaminated wounds, prolonged surgeries, the use of drains, and extended hospital stays, contribute to a higher incidence of surgical site infections (SSI). These growing challenges, coupled with an increase in surgical procedures and the expanding elderly population, are expected to drive demand for effective surgical site infection management across India.
The market is segmented based on industry vertical, procedure, type of infection, and product. The industry vertical segment includes ambulatory surgical centers and hospitals.
Ambulatory care refers to medical services provided in facilities where patients do not stay overnight, such as outpatient clinics, physicians’ offices, urgent care centers, and rehabilitation centers. Healthcare-associated infections remain a common complication after ambulatory surgeries. However, most of these infections are preventable due to stringent regulations that ensure ambulatory surgical centers (ASCs) maintain the same high safety standards as hospitals. Advances in technology, anesthesia, and minimally invasive procedures have made surgeries at ASCs safer. Additionally, ASCs are prohibited from sharing space with hospitals, critical access hospital outpatient surgery departments, or Medicare-participating independent diagnostic testing facilities (IDTFs), even if they operate at different times.
Contender Analysis in the Surgical Site Infection Control Market:
Johnson & Johnson, based in the United States, is involved in the research, development, manufacturing, and marketing of personal care products, pharmaceuticals, and surgical equipment. The company operates through three main segments: medical devices, pharmaceuticals, and consumer health. The medical devices segment supplies products to wholesalers, retailers, and hospitals, primarily used by healthcare professionals in various settings. These products address needs in orthopedics, cancer treatment, cardiovascular care, general surgery, neurology, blood glucose monitoring, infection prevention, and more. Founded in 1886, Johnson & Johnson serves clients across multiple regions, including Asia-Pacific.
In May 2024, Ethicon, a Johnson & Johnson MedTech company, launched the ECHELON LINEAR™ Cutter. This device integrates 3D-Stapling Technology and Gripping Surface Technology (GST) that reduces staple line leaks by 47%, reducing surgical risks.
Other notable companies offering solutions in the market include Sotera Health LLC, Steris Corporation, Stryker Corporation, and Kimberly-Clark Corporation.
KEY DELIVERABLES OF THE REPORT:
Market CAGR during the forecasting years 2024-2032
Detailed data highlighting key insights, industry components, and market strategies
Comprehensive information and estimation of the surgical site infection control market revenue growth in the Asia-Pacific and its influence on the parent market
In-depth study of forthcoming trends in consumer behavioral patterns
A meticulous analysis of the competitive landscape and Porter’s Five Forces
A wide-ranging study of factors that will challenge the APAC surgical site infection control market’s growth during the upcoming years
Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT
ANALYSIS ON THE SURGICAL SITE INFECTION CONTROL MARKET
2.1.1. COVID-19
IMPACT
2.2. PORTER’S
FIVE FORCES ANALYSIS
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. THREAT
OF SUBSTITUTES
2.2.3. BARGAINING
POWER OF BUYERS
2.2.4. BARGAINING
POWER OF SUPPLIERS
2.2.5. THREAT
OF COMPETITIVE RIVALRY
2.3. KEY
MARKET STRATEGIES
2.3.1. PRODUCT
LAUNCHES
2.3.2. ACQUISITIONS
2.3.3. BUSINESS
DIVESTITURES & EXPANSIONS
2.4. MARKET
DRIVERS
2.4.1. ESCALATING
INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
2.4.2. GROWING
GERIATRIC POPULATION
2.4.3. REGULATORY
GUIDELINES FOR PREVENTING HOSPITAL-ACQUIRED INFECTION
2.5. MARKET
CHALLENGES
2.5.1. INCREASE
IN OUTPATIENT TREATMENT
2.5.2. SURGE
IN MEDICAL WASTE DUE TO THE USE OF DISPOSABLE MEDICAL ITEMS
2.5.3. INSUFFICIENT
AWARENESS REGARDING HOSPITAL-ACQUIRED INFECTIONS
2.6. MARKET
OPPORTUNITIES
2.6.1. GROWTH
OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES
2.6.2. RISE
IN SURGICAL PROCEDURE RATES
2.6.3. TECHNOLOGICAL
ADVANCEMENTS IN PREVENTING SURGICAL SITE INFECTIONS
2.7. ANALYST
PERSPECTIVE
3. ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET – BY PROCEDURE
3.1. LAPAROSCOPY
3.2. ORTHOPEDIC
SURGERY
3.3. CARDIOVASCULAR
3.4. OBSTETRICS
AND GYNECOLOGY
3.5. WOUND
CLOSURE
3.6. PLASTIC
& RECONSTRUCTIVE SURGERY
3.7. THORACIC
SURGERY
3.8. MICROVASCULAR
3.9. UROLOGY
3.10. NEUROSURGERY
3.11. OTHER
PROCEDURES
4. ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET – BY TYPE OF INFECTION
4.1. SUPERFICIAL
INCISIONAL SSI
4.2. DEEP
INCISIONAL SSI
4.3. ORGAN
OR SPACE SSI
5. ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET – BY INDUSTRY VERTICAL
5.1. HOSPITALS
5.2. AMBULATORY
SURGICAL CENTERS
6. ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET – BY PRODUCT
6.1. DISINFECTANTS
6.1.1. SKIN
DISINFECTANTS
6.1.2. HAND
DISINFECTANTS
6.2. MANUAL
REPROCESSORS SOLUTIONS
6.3. SURGICAL
DRAPES
6.4. SURGICAL
GLOVES
6.5. SKIN
PREPARATION SOLUTIONS
6.6. SURGICAL
IRRIGATION
6.7. SURGICAL
SCRUBS
6.8. HAIR
CLIPPERS
6.9. MEDICAL
NONWOVENS
6.10. OTHER
PRODUCTS
7. ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET – BY COUNTRY OUTLOOK
7.1. ASIA-PACIFIC
7.1.1. COUNTRY
ANALYSIS
7.1.1.1. CHINA
7.1.1.1.1. CHINA SURGICAL
SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.2. JAPAN
7.1.1.2.1. JAPAN SURGICAL
SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.3. INDIA
7.1.1.3.1. INDIA SURGICAL
SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.4. SOUTH
KOREA
7.1.1.4.1. SOUTH
KOREA SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.5. ASEAN
COUNTRIES
7.1.1.5.1. ASEAN
COUNTRIES SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.6. AUSTRALIA
& NEW ZEALAND
7.1.1.6.1. AUSTRALIA
& NEW ZEALAND SURGICAL SITE INFECTION CONTROL MARKET FORECAST &
PROSPECTS
7.1.1.7. REST
OF ASIA-PACIFIC
7.1.1.7.1. REST
OF ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET FORECAST &
PROSPECTS
8. COMPETITIVE
LANDSCAPE
8.1. AMERICAN
POLYFILM INC
8.1.1. OVERVIEW
8.1.2. PORTFOLIO
8.1.3. KEY
STRENGTHS
8.1.4. KEY
CHALLENGES
8.2. 3M
8.2.1. OVERVIEW
8.2.2. PORTFOLIO
8.2.3. KEY
STRENGTHS
8.2.4. KEY
CHALLENGES
8.3. ANSELL
LIMITED
8.3.1. OVERVIEW
8.3.2. PORTFOLIO
8.3.3. KEY
STRENGTHS
8.3.4. KEY
CHALLENGES
8.4. BELIMED
LIFE SCIENCE AG
8.4.1. OVERVIEW
8.4.2. PORTFOLIO
8.4.3. KEY
STRENGTHS
8.4.4. KEY
CHALLENGES
8.5. BECTON,
DICKINSON AND COMPANY (BD)
8.5.1. OVERVIEW
8.5.2. PORTFOLIO
8.5.3. KEY
STRENGTHS
8.5.4. KEY
CHALLENGES
8.6. BIOMERIEUX
SA
8.6.1. OVERVIEW
8.6.2. PORTFOLIO
8.6.3. KEY
STRENGTHS
8.6.4. KEY
CHALLENGES
8.7. GETINGE
AB
8.7.1. OVERVIEW
8.7.2. PORTFOLIO
8.7.3. KEY
STRENGTHS
8.7.4. KEY
CHALLENGES
8.8. GAMA
HEALTHCARE
8.8.1. OVERVIEW
8.8.2. PORTFOLIO
8.8.3. KEY
STRENGTHS
8.8.4. KEY
CHALLENGES
8.9. JOHNSON
& JOHNSON
8.9.1. OVERVIEW
8.9.2. PORTFOLIO
8.9.3. KEY
STRENGTHS
8.9.4. KEY
CHALLENGES
8.10. SOTERA
HEALTH LLC
8.10.1. OVERVIEW
8.10.2. PORTFOLIO
8.10.3. KEY STRENGTHS
8.10.4. KEY
CHALLENGES
8.11. KIMBERLY-CLARK
CORPORATION
8.11.1. OVERVIEW
8.11.2. PORTFOLIO
8.11.3. KEY
STRENGTHS
8.11.4. KEY
CHALLENGES
8.12. STERIS
CORPORATION
8.12.1. OVERVIEW
8.12.2. PORTFOLIO
8.12.3. KEY
STRENGTHS
8.12.4. KEY
CHALLENGES
8.13. STRYKER
CORPORATION
8.13.1. OVERVIEW
8.13.2. PORTFOLIO
8.13.3. KEY
STRENGTHS
8.13.4. KEY
CHALLENGES
9. RESEARCH
METHODOLOGY & SCOPE
9.1. RESEARCH
SCOPE & DELIVERABLES
9.2. SOURCES
OF DATA
9.3. RESEARCH
METHODOLOGY
TABLE 1: ASIA-PACIFIC SURGICAL
SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 2: LIST OF PRODUCT
LAUNCHES
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF BUSINESS
DIVESTITURES & EXPANSIONS
TABLE 5: ASIA-PACIFIC SURGICAL
SITE INFECTION CONTROL MARKET, BY PROCEDURE, 2024-2032 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC SURGICAL
SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, 2024-2032 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC SURGICAL
SITE INFECTION CONTROL MARKET, BY INDUSTRY VERTICAL, 2024-2032 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC SURGICAL
SITE INFECTION CONTROL MARKET, BY PRODUCT, 2024-2032 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC SURGICAL
SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE FORCES
ANALYSIS
FIGURE 2: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY PROCEDURE, 2023 & 2032 (IN %)
FIGURE 3: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY LAPAROSCOPY, 2024-2032 (IN $
MILLION)
FIGURE 4: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY ORTHOPEDIC SURGERY, 2024-2032 (IN $
MILLION)
FIGURE 5: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY CARDIOVASCULAR, 2024-2032 (IN $
MILLION)
FIGURE 6: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY OBSTETRICS AND GYNECOLOGY, 2024-2032
(IN $ MILLION)
FIGURE 7: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY WOUND CLOSURE, 2024-2032 (IN $
MILLION)
FIGURE 8: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY PLASTIC & RECONSTRUCTIVE
SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY THORACIC SURGERY, 2024-2032 (IN $
MILLION)
FIGURE 10: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY MICROVASCULAR, 2024-2032 (IN $
MILLION)
FIGURE 11: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY UROLOGY, 2024-2032 (IN $
MILLION)
FIGURE 12: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY NEUROSURGERY, 2024-2032 (IN $
MILLION)
FIGURE 13: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PROCEDURES, 2024-2032 (IN $
MILLION)
FIGURE 14: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, 2023 & 2032
(IN %)
FIGURE 15: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY SUPERFICIAL INCISIONAL SSI,
2024-2032 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY DEEP INCISIONAL SSI, 2024-2032 (IN $
MILLION)
FIGURE 17: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY ORGAN OR SPACE SSI, 2024-2032 (IN $
MILLION)
FIGURE 18: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY INDUSTRY VERTICAL, 2023 & 2032
(IN %)
FIGURE 19: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY HOSPITALS, 2024-2032 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY AMBULATORY SURGICAL CENTERS,
2024-2032 (IN $ MILLION)
FIGURE 21: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY PRODUCT, 2023 & 2032 (IN %)
FIGURE 22: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, 2024-2032 (IN $
MILLION)
FIGURE 23: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, 2023 & 2032 (IN
%)
FIGURE 24: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN DISINFECTANTS, 2024-2032 (IN $
MILLION)
FIGURE 25: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY HAND DISINFECTANTS, 2024-2032 (IN $
MILLION)
FIGURE 26: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY MANUAL REPROCESSORS SOLUTIONS,
2024-2032 (IN $ MILLION)
FIGURE 27: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL DRAPES, 2024-2032 (IN $
MILLION)
FIGURE 28: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL GLOVES, 2024-2032 (IN $
MILLION)
FIGURE 29: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN PREPARATION SOLUTIONS,
2024-2032 (IN $ MILLION)
FIGURE 30: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL IRRIGATION, 2024-2032 (IN $
MILLION)
FIGURE 31: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL SCRUBS, 2024-2032 (IN $
MILLION)
FIGURE 32: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY HAIR CLIPPERS, 2024-2032 (IN $
MILLION)
FIGURE 33: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY MEDICAL NONWOVENS, 2024-2032 (IN $
MILLION)
FIGURE 34: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PRODUCTS, 2024-2032 (IN $
MILLION)
FIGURE 35: ASIA-PACIFIC
SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2023 & 2032 (IN
%)
FIGURE 36: CHINA SURGICAL SITE
INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 37: JAPAN SURGICAL SITE
INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 38: INDIA SURGICAL SITE
INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 39: SOUTH KOREA
SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 40: ASEAN COUNTRIES
SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 41: AUSTRALIA & NEW
ZEALAND SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 42: REST OF
ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)